Inflammatory Intestinal Diseases最新文献

{"title":"Impact of Bowel Rest on Hospitalized Patients with Ulcerative Colitis.","authors":"Nobuaki Shu, Yuki Ohta, Jun Kato, Kento Shimizu, Hiromi Arakawa, Yoshiki Matsubara, Takuya Ohashi, Tomomi Ozaki, Toshiyuki Ito, Ryo Saito, Yusuke Ozeki, Miyuki Iwasaki, Makoto Furuya, Chihiro Goto, Ryosuke Horio, Akane Kurosugi, Michiko Sonoda, Tsubasa Ishikawa, Hirotaka Oura, Tatsuya Kaneko, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Tomoaki Matsumura","doi":"10.1159/000552264","DOIUrl":"10.1159/000552264","url":null,"abstract":"<p><strong>Introduction: </strong>Bowel rest has traditionally been practiced for hospitalized patients with severe ulcerative colitis (UC). Most available evidence for bowel rest in UC originates from the prebiologic era. Therefore, this study evaluated the clinical impact of bowel rest in hospitalized patients with UC under modern therapy.</p><p><strong>Methods: </strong>A retrospective study was performed at a single tertiary hospital, where a change in institutional policy for hospitalized UC patients replaced essential bowel rest with early oral feeding in October 2019. Hospitalized UC patients were classified according to the timing of admission into a bowel rest group (group BR; February 2017-September 2019) and a non-bowel rest group (group non-BR; October 2019-October 2023). The primary outcome was colectomy avoidance. Secondary outcomes included hospital length of stay (LOS), central venous catheter (CVC) use, and related complications such as venous thromboembolism (VTE) and catheter-related bloodstream infection (CRBSI).</p><p><strong>Results: </strong>A total of 76 patients were analyzed (38 per group). Colectomy avoidance rate was similar in both groups (84.2% each, <i>p</i> = 0.98, log-rank test). Median LOS was shorter in group non-BR (22 vs. 31 days; <i>p</i> = 0.002). CVC use was more frequent (84.2% vs. 31.6%; <i>p</i> < 0.001) and longer (26 vs. 15 days; <i>p</i> = 0.001) in group BR. VTE and CRBSI rates did not differ between the two groups.</p><p><strong>Conclusions: </strong>Among UC patients able to tolerate oral intake, oral intake was associated with shorter hospitalization and reduced CVC use, suggesting that routine bowel rest may not provide additional benefit.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"222-231"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin Signatures as Histology-Aligned Biomarkers in Inflammatory Bowel Disease.","authors":"Nikolaos Martinos, Andreas C Lazaris, Christos Kroupis, Georgios Kranidiotis, Georgia-Eleni Thomopoulou","doi":"10.1159/000552149","DOIUrl":"10.1159/000552149","url":null,"abstract":"<p><strong>Introduction: </strong>Histological remission is the most predictive endpoint in inflammatory bowel disease (IBD), yet repeated biopsies are invasive. Interleukins (ILs) are emerging biomarkers that may capture histology-aligned activity. We systematically evaluated IL-6, IL-23, IL-17A, IL-1β, IL-8, and IL-10 as diagnostic and prognostic biomarkers in ulcerative colitis (UC) and Crohn's disease (CD).</p><p><strong>Methods: </strong>MEDLINE, EMBASE, Scopus, and Web of Science were searched (January 1989-March 2025). Eligible studies quantified ILs in serum, plasma, stool, or tissue and reported diagnostic/prognostic outcomes against validated histology indices. Risk of bias was assessed with QUADAS-2 (diagnostic) and QUIPS (prognostic). Certainty was graded using GRADE. The feasibility of quantitative synthesis for individual ILs was explored; however, differences in assay platforms, reporting metrics, and biological matrices prevented valid statistical pooling.</p><p><strong>Results: </strong>Twenty-seven adult cohorts met the inclusion criteria. Serum IL-6 and IL-23 consistently showed the strongest diagnostic performance across studies, with reported AUC values generally ranging between approximately 0.80 and 0.86. Tissue IL-23/IL-17A aligned with neutrophils, crypt injury, and apoptosis, detecting subclinical inflammation and forecasting relapse (notably in ileal CD). IL-1β/IL-8 modestly reflected neutrophil-rich lesions. IL-10 inversely correlated with activity and higher remission levels predicted longer flare-free survival.</p><p><strong>Conclusion: </strong>IL-6 and IL-23 are the strongest serum biomarkers for histology-aligned activity; tissue IL-17A adds lesion-level resolution, while IL-10 provides prognostic value. IL profiling may complement CRP and fecal calprotectin (fCal) in future precision medicine strategies but requires further prospective validation before routine clinical application.</p><p><strong>Key messages: </strong>Histological remission is the most reliable endpoint in IBD but requires invasive biopsies. IL profiling offers a biologically specific, noninvasive alternative that aligns with histological activity. Among candidate cytokines, serum IL-6 and IL-23 consistently show the strongest diagnostic performance, while tissue IL-17A enhances lesion-level resolution and IL-10 provides prognostic value for remission stability. IL signatures therefore complement C-reactive protein and fCal, supporting precision medicine strategies for individualized monitoring and therapy optimization in IBD.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"210-221"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13299169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix Cohort.","authors":"Shinsuke Otagiri, Keiya Aoyama, Takehiko Katsurada, Takahiro Ito, Atsuo Maemoto, Fumika Orii, Toshifumi Ashida, Masanao Nasuno, Hiroki Tanaka, Katsuyoshi Ando, Mikihiro Fujiya, Yoshihiro Yokoyama, Satoshi Motoya, Hiroshi Nakase","doi":"10.1159/000552221","DOIUrl":"10.1159/000552221","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world data on the long-term effectiveness of vedolizumab (VDZ) in East Asian patients with Crohn's disease (CD) remain limited. This study aimed to assess treatment persistence, clinical and endoscopic effectiveness, safety, and predictors of VDZ discontinuation in a multicenter Japanese cohort.</p><p><strong>Methods: </strong>A retrospective study was conducted across seven hospitals between June 2019 and October 2025, including patients with CD who initiated VDZ. Outcomes included VDZ continuation, factors associated with discontinuation, longitudinal changes in clinical and endoscopic indices, and adverse events.</p><p><strong>Results: </strong>Seventy-three patients were included. VDZ continuation was 62.3% and 37.8% at 1 and 3 years, respectively. In a multivariable Cox analysis, higher baseline C-reactive protein (CRP), higher body mass index (BMI), and female sex were independently associated with increased risk of VDZ discontinuation, with a trend toward better persistence among patients with ileal disease. In the 1-year analysis, female sex and prior biologic exposure predicted early discontinuation. CD activity index and its subscores improved during early treatment, and albumin levels increased gradually over time. Simple endoscopic score for CD improved at 1 and 2 years. Among patients with active disease, >40% achieved remission from week 6 onward. Adverse events occurred in 16.4%, with two (2.7%) patients discontinuing VDZ due to infusion reactions or psoriasiform rashes.</p><p><strong>Conclusion: </strong>VDZ demonstrated acceptable long-term durability, clinically meaningful and endoscopic improvement, and a favorable safety profile in Japanese real-world practice. Baseline CRP, BMI, and sex were important predictors of treatment persistence.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"232-243"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal Endometriosis Mimicking Ulcerative Colitis-Associated Neoplasia: A Case Report.","authors":"Ke Han, Hiroki Kiyohara, Shinya Sugimoto, Kaoru Takabayashi, Miho Kawaida, Koji Okabayashi, Kohei Shigeta, Yusuke Yoshimatsu, Tomohisa Sujino, Naoki Hosoe, Motohiko Kato, Nobuhiro Nakamoto, Yasushi Iwao, Yohei Mikami, Takanori Kanai","doi":"10.1159/000551335","DOIUrl":"10.1159/000551335","url":null,"abstract":"<p><strong>Introduction: </strong>Intestinal endometriosis is a benign condition characterized by the presence of endometrial tissue within the bowel wall, often mimicking colorectal malignancy. Its coexistence with ulcerative colitis (UC) is rare and can complicate the diagnosis.</p><p><strong>Case presentation: </strong>A 35-year-old woman with long-standing UC presented with severe diarrhea and rectal bleeding. Colonoscopy revealed severe disease activity with multiple deep ulcerations and a newly developed stricture in the sigmoid colon. Pathological examinations, including bite-on-bite biopsies, showed no evidence of malignancy. However, colitis-associated neoplasia (CAN) could not be completely ruled out because such lesions may primarily involve the deep layers of the colonic wall. Given the severity of disease and concern for possible CAN, a total colectomy was performed. Histopathological and immunohistochemical analysis of the resected specimen ultimately identified intestinal endometriosis as the cause of the stricture.</p><p><strong>Conclusion: </strong>This case underscores the importance of considering intestinal endometriosis in women with UC who develop unexplained colonic strictures, particularly when malignancy cannot be confirmed.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"205-209"},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13249418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Outcomes of Risankizumab in Crohn's Disease: A Real-World Analysis of Terminal Ileal Lesions.","authors":"Kazuhiko Uchiyama, Tomohisa Takagi, Ryohei Obata, Eiki Murakami, Kohei Asaeda, Mariko Kajiwara-Kubota, Yuma Hotta, Makoto Tanaka, Ken Inoue, Tatsushi Omatsu, Kazuhiro Katada, Yuji Naito","doi":"10.1159/000551419","DOIUrl":"10.1159/000551419","url":null,"abstract":"<p><strong>Introduction: </strong>Improvement of small intestinal lesions is essential for achieving favorable long-term outcomes in patients with Crohn's disease (CD); however, evidence regarding the efficacy of biologics for small bowel involvement remains limited. Risankizumab (RZB), a selective interleukin-23 (IL-23) p19 inhibitor, has shown efficacy in large randomized trials; however, data on its effect on small intestinal inflammation are limited. This study aimed to evaluate the real-world effectiveness of RZB on small intestinal lesions using balloon-assisted enteroscopy.</p><p><strong>Methods: </strong>We conducted a retrospective study of patients with CD who received RZB between July 2023 and January 2025. Clinical activity was assessed using the Harvey-Bradshaw Index (HBI), and serum biomarkers (albumin, C-reactive protein, and hemoglobin) were measured longitudinally. Endoscopic activity was evaluated using the Simple Endoscopic Score for CD (SES-CD) before treatment and at 28 weeks after treatment; paired endoscopic assessment was available in 16 patients.</p><p><strong>Results: </strong>A total of 23 patients met the inclusion criteria. At baseline, 10 patients had clinically active disease (HBI ≥4), and 13 were in clinical remission (HBI ≤3). In the active group, HBI and C-reactive protein levels decreased after treatment, whereas hemoglobin and albumin concentrations increased during follow-up (HBI: <i>p</i> < 0.01; CRP: <i>p</i> < 0.05; hemoglobin: <i>p</i> < 0.05; albumin: <i>p</i> < 0.05). Among the 16 patients who underwent paired endoscopic evaluation, both total and ileal SES-CD scores decreased after 28 weeks of RZB therapy, demonstrating mucosal improvement in the terminal ileum (total SES-CD: <i>p</i> < 0.0001; ileal SES-CD: <i>p</i> = 0.0001). Notably, several patients who showed inadequate response to ustekinumab (UST) also exhibited endoscopic improvement after RZB treatment.</p><p><strong>Conclusions: </strong>RZB was effective in improving clinical and endoscopic disease activities, including terminal ileal lesions, even in patients who were previously refractory to UST. Given the prognostic importance of small bowel inflammation, these findings highlight the potential of selective IL-23p19 inhibition as a valuable therapeutic option for patients with small bowel-dominant CD.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"169-178"},"PeriodicalIF":0.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13193699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual Variations in Anti-αvβ6 Autoantibody Levels Determined by <i>ITGAV</i> Gene Polymorphisms: Associations with Genetic Background and Relapse in Ulcerative Colitis.","authors":"Satoshi Ono, Yoshiharu Yamaguchi, Akane Sugimura, Shunsuke Kato, Kazunori Adachi, Masahide Ebi, Naotaka Ogasawara, Makoto Sasaki, Masanao Nakamura","doi":"10.1159/000551546","DOIUrl":"10.1159/000551546","url":null,"abstract":"<p><strong>Introduction: </strong>Increased expression of the epithelial-specific adhesion molecule integrin αvβ6 and the presence of anti-αvβ6 autoantibodies (V6 Ab) have been reported in ulcerative colitis (UC). However, the influence of single-nucleotide polymorphisms (SNPs) in the <i>ITGAV</i> gene on antibody titers, as well as their association with relapse in patients with mild disease, have not been fully elucidated. This study aimed to clarify the impact of <i>ITGAV</i> gene polymorphisms on serum V6 Ab levels in patients with UC. As secondary objectives, we evaluated the association between these SNPs and 1-year relapse and assessed the relapse predictive performance of V6 Ab levels using receiver operating characteristic (ROC) analysis.</p><p><strong>Methods: </strong>We retrospectively analyzed 61 patients with UC whose V6 Ab levels were measured at our institution between January 2023 and June 2025. Associations between four <i>ITGAV</i> SNPs (rs3911238, rs3768777, rs1448427, and rs10174098) and V6 Ab levels were examined. Among 49 patients with a partial Mayo score of 0 or 1, we evaluated the relationship between SNP variants and 1-year relapse. The predictive ability of V6 Ab for relapse was assessed using ROC analysis.</p><p><strong>Results: </strong>For all four <i>ITGAV</i> SNPs, carriers of variant alleles exhibited significantly higher serum V6 Ab levels compared with wild-type individuals. Among 49 patients with a partial Mayo score of 0 or 1, 14 (28.6%) experienced relapse within 1 year. The relapse group showed significantly higher frequencies of rs3768777, rs10174098, and rs1448427 variants than the non-relapse group. The predictive performance of V6 Ab levels for relapse yielded an area under the ROC curve of 0.78 (95% confidence interval: 0.64-0.89). At a threshold of 6.58 U/mL, sensitivity, specificity, and negative predictive value were 1.00, 0.54, and 1.00, respectively.</p><p><strong>Conclusion: </strong><i>ITGAV</i> gene polymorphisms determined inter-individual variation in V6 Ab levels, with variant carriers exhibiting higher antibody titers and increased risk of relapse. Low V6 Ab levels were a reliable indicator for excluding relapse. The combined use of antibody titers with <i>ITGAV</i> SNP information may facilitate precision stratification of patients with UC in remission or with mild disease.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"179-188"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148137931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Paediatric-Onset Inflammatory Bowel Disease on Educational Paths and Careers.","authors":"Cléa Kunz, Alain Schoepfer, Jean-Benoît Rossel, Christiane Sokollik, Alexa Giroud Rivier, Franziska Righini Grunder, Carsten Posovszky, Andreas Nydegger","doi":"10.1159/000551490","DOIUrl":"10.1159/000551490","url":null,"abstract":"<p><strong>Introduction: </strong>Given the paucity of data, we aimed to determine the impact of paediatric-onset inflammatory bowel disease on educational paths and careers.</p><p><strong>Methods: </strong>Data from the national prospective Swiss Inflammatory Bowel Disease (IBD) Cohort Study from May 2006 to October 2019 were analysed. Patients were stratified into the following groups according to their age at diagnosis: paediatric (0-17 years), early adult (age 18-30 years), and late adult (age 30-65 years). The three groups were compared regarding educational level, unemployment, absenteeism from work, and disability pension.</p><p><strong>Results: </strong>Among 2,199 patients, 7.6%, 42.3%, and 50.0% belonged to the paediatric, early adult, and late adult IBD diagnosis group, respectively (55.6% with Crohn's disease [CD] and 44.4% with ulcerative colitis [UC]). Median age at diagnosis was 16.0, 24.2, and 44.3 years old, respectively. A total of 32.8% of paediatric CD patients achieved high educational levels (32.3% early adults, 31.6% late adults, <i>p</i> < 0.001). A total of 46.4% of early adult UC achieve high educational levels (40.8% paediatric, 35.9% late adult, <i>p</i> = 0.002). No significant differences were found between the three age groups with respect to unemployment rate and invalidity rent at both enrolment and last follow-up. Absenteeism was greater in paediatric CD (27.7% vs. 17.8% vs. 16.8%, <i>p</i> = 0.024) and paediatric UC (24.5% vs. 18.2% vs. 14.4%, <i>p</i> = 0.092) at enrolment. Depression and number of hospitalizations or medical consultations are associated with lower educational levels, greater absenteeism, and invalidity rate.</p><p><strong>Conclusions: </strong>Higher educational levels are attained by paediatric-onset CD and early adult UC patients, with greater absenteeism in paediatric and early adult-onset IBD.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"189-204"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13225829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Activity, Disease Activity, Quality of Life, and Social Support among Japanese People with Inflammatory Bowel Disease: A Cross-Sectional Study.","authors":"Kaori Aihoshi, Maya Nunotani, Takuro Miyazaki, Shin Fujioka, Kenichi Goto","doi":"10.1159/000551465","DOIUrl":"10.1159/000551465","url":null,"abstract":"<p><strong>Introduction: </strong>Physical activity levels are often lower in people with inflammatory bowel disease (IBD) than in healthy individuals. However, no studies have examined physical activity levels and associated factors among Japanese people with IBD. This study aimed to examine physical activity levels and their associations with other factors, including disease activity and quality of life (QOL).</p><p><strong>Methods: </strong>A nationwide online survey was conducted through an online community for people with IBD. Physical activity was assessed using the short version of the International Physical Activity Questionnaire and classified into low and moderate-to-vigorous intensity groups based on World Health Organization guidelines. Disease activity was evaluated using the Simple Clinical Colitis Activity Index (SCCAI) for ulcerative colitis and the Harvey-Bradshaw Index (HBI) for Crohn's disease. QOL was measured using the Inflammatory Bowel Disease Questionnaire-32 (IBDQ-32). Binary logistic regression was used to identify factors associated with physical activity level, and simple linear regression to evaluate associations between physical activity and both disease activity and QOL.</p><p><strong>Results: </strong>Overall, 232 participants (mean age 39.9 years, 62.1% women) completed the survey, with 45.3% in the low intensity group and 54.7% in the moderate-to-vigorous intensity group. Most participants were in remission or had mild disease activity (mean SCCAI score 2.85; mean HBI score 4.40). The median weekday sitting time was 420 min/day. None of the demographic, physical, or social support variables were significantly associated with physical activity level. Physical activity level was not significantly associated with disease activity in either ulcerative colitis (<i>p</i> = 0.24) or Crohn's disease (<i>p</i> = 0.50) but had a significant positive association with IBDQ-32 total score (<i>p</i> = 0.03) and the emotional function (<i>p</i> = 0.03) and social function (<i>p</i> = 0.04) subscales.</p><p><strong>Conclusion: </strong>Physical activity levels among Japanese people with IBD were similar to those in other countries, but sitting time was longer. In our study population, who mostly had no more than mild disease, physical activity was not adversely associated with disease activity and had positive associations with emotional and social QOL. We suggest that physical activity can therefore be safely recommended to this population, with implications for nursing practice.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"157-168"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147928799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Crohn's Disease-Associated Cancer with a Focus on Endoscopic Surveillance.","authors":"Yumie Kobayashi, Shuhei Hosomi, Koji Fujimoto, Rieko Nakata, Yu Nishida, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Koji Otani, Shusei Fukunaga, Fumio Tanaka, Kiyoshi Maeda, Yasuhiro Fujiwara","doi":"10.1159/000551283","DOIUrl":"10.1159/000551283","url":null,"abstract":"<p><strong>Introduction: </strong>Long-term Crohn's disease (CD) increases risk of cancer. However, data on the clinical characteristics and optimal endoscopic surveillance strategies for CD-associated cancers in Japan remain controversial. This study aimed to investigate the clinical characteristics, diagnostic methods, and treatment patterns of CD-associated cancers at our institution and to consider strategies for effective surveillance in Japanese clinical practice.</p><p><strong>Methods: </strong>We retrospectively analyzed 21 patients with 26 CD-associated cancer locations treated at our hospital between August 2001 and March 2024, focusing on their clinical backgrounds, cancer characteristics, and endoscopic surveillance practices.</p><p><strong>Results: </strong>Anorectal cancer was the most common (61%), and 57% were stage II or higher at the time of diagnosis. There were 12 cases of fistula-associated cancer, with a median disease duration of 18.5 years, and 7 cases of stage II or higher. Targeted endoscopic biopsy established the diagnosis in 77%, often requiring multiple-site biopsies. Remission or mild endoscopic activity was observed in 75% (6/8) of stage 0-I patients, compared with 20% (2/10) of stage II-IV patients, suggesting a trend toward more advanced cancer with higher endoscopic activity (<i>p</i> = 0.03). Compared with non-anorectal cancers, 33% of anorectal cancers required four or more endoscopic biopsies for diagnosis, and this rate was significantly higher than that of non-anorectal cancers (<i>p</i> = 0.028).</p><p><strong>Conclusion: </strong>Anorectal cancer was the most common CD-associated cancer, and strictures and active inflammation made early diagnosis difficult. Annual surveillance with multiple-site biopsies of anal lesions was essential.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"147-156"},"PeriodicalIF":0.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leucine-Rich Alpha-2 Glycoprotein Is an Accurate Serum Marker for Endoscopic and Histological Remission in Ulcerative Colitis.","authors":"Ami Kawamoto, Toshimitsu Fujii, Shohei Tanaka, Sho Watanabe, Shohei Tomii, Kento Takenaka, Shuji Hibiya, Ryo Morikawa, Akiko Tamura, Hiromichi Shimizu, Masayuki Kurosaki, Tsunehito Yauchi, Kazuo Ohtsuka, Ryuichi Okamoto","doi":"10.1159/000550946","DOIUrl":"10.1159/000550946","url":null,"abstract":"<p><strong>Introduction: </strong>Achieving both endoscopic and histological remission in ulcerative colitis (UC) is associated with improved clinical outcomes. There is a growing need for noninvasive methods to assess both remission states. This study investigates the utility of serum leucine-rich alpha-2 glycoprotein (LRG) as a biomarker for monitoring endoscopic and histological remission in patients with UC.</p><p><strong>Methods: </strong>Patients with UC who underwent colonoscopy from July 2020 to September 2021 at multiple centers in Japan were included to compare the accuracy of C-reactive protein (CRP) and LRG in detecting endoscopic and histological remission. Receiver operating characteristic curve analyses were performed and area under the curve (AUC) values were compared.</p><p><strong>Results: </strong>A total of 412 patients were identified. The median values of CRP and LRG were 0.07 mg/dL and 12.2 μg/mL, respectively. Endoscopic remission, as defined as Mayo endoscopic sub-score of 0 or 1, was observed in 188 patients, and histological remission, as defined as Geboes score <3.1, was observed in 156 patients. The AUC values for CRP and LRG for detecting endoscopic remission were 0.68 and 0.76, respectively, and the AUC values for CRP and LRG for detecting histological remission were 0.70 and 0.76, respectively. In both cases, the AUC for LRG was significantly higher than that of CRP (<i>p</i> < 0.0001). The optimal cutoff value of LRG for detecting histological remission was 13.4 μg/mL, with a sensitivity of 82% and a specificity of 58%.</p><p><strong>Conclusion: </strong>LRG is superior to CRP in detecting both endoscopic and histological remission in patients with UC.</p>","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"11 1","pages":"139-146"},"PeriodicalIF":0.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147813856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}